• Pharmacology
  • Allergy, Immunology, and ENT
  • Cardiology
  • Emergency Medicine
  • Endocrinology
  • Adolescent Medicine
  • Gastroenterology
  • Infectious Diseases
  • Neurology
  • OB/GYN
  • Practice Improvement
  • Gynecology
  • Respiratory
  • Dermatology
  • Mental, Behavioral and Development Health
  • Oncology
  • Rheumatology
  • Sexual Health
  • Pain

Considerations for Moderna's move to get an EUA for the COVID-19 vaccine in young kids

Video

Editorial board member Donna Hallas, PhD, CPNP, PPCNP-BC, PMHS, FAANP, FAAN, discusses the recently release topline data, the potential timeline, and what potential stumbling blocks could be.

Editorial board member Donna Hallas, PhD, CPNP, PPCNP-BC, PMHS, FAANP, FAAN, discusses the recently release topline data, the potential timeline, and what potential stumbling blocks could be.

Related Videos
Rupa Wong, MD | Image Credit: Rupa Wong, MD
Tina Tan, MD, FAAP, FIDSA, FPIDS, editor in chief, Contemporary Pediatrics, professor of pediatrics, Feinberg School of Medicine, Northwestern University, pediatric infectious diseases attending, Ann & Robert H. Lurie Children's Hospital of Chicago
John Bradley, MD
FDA approves B-VEC to treat dystrophic epidermolysis bullosa patients 6 months and older | Image Credit: bankrx - Image Credit: bankrx - stock.adobe.com.
Pfizer's infant RSV vaccine receives FDA Advisory Committee's support | Image Credit: Dr_Microbe - Image Credit: Dr_Microbe
Tina Tan, MD
Related Content
FDA accepts BLA for meningococcal ABCWY vaccine, target action date set | Image Credit: © Araki Illustrations - © Araki Illustrations - stock.adobe.com.

FDA accepts BLA for meningococcal ABCWY vaccine, target action date set

April 16th 2024
Article

The 5-in-1 vaccine candidate has the potential to reduce shots and simplify the immunization process.

Juanita Mora, MD

What the FDA approval of benralizumab means for children with severe asthma

April 11th 2024
Article

Juanita Mora, MD, breaks down the FDA approval of benralizumab as an add-on maintenance therapy among patients with severe asthma aged 6 to 11 years.

Image Credit: © Calin - © Calin - stock.adobe.com.

FDA approves dolutegravir/lamivudine to treat HIV infection in adolescents

April 8th 2024
Article

The treatment is approved for adolescents aged 12 years and older.

Zevtera approved for community-acquired bacterial pneumonia in infants, adolescents, teens | Image Credit: © Calin - © Calin - stock.adobe.com.

Zevtera approved for community-acquired bacterial pneumonia in infants, adolescents, teens

April 4th 2024
Article

The pediatric approval to treat CABP is 1 of 3 indications approved by the FDA.

Inaxaplin to treat APOL1-mediated kidney disease moves to phase 3 trial | Image Credit: © Sebastian Kaulitzki - © Sebastian Kaulitzki - stock.adobe.com.

Inaxaplin to treat APOL1-mediated kidney disease moves to phase 3 trial

April 3rd 2024
Article

The phase 3 portion of the AMPLITUDE trial will include adolescents aged 10 to 17 years.

DMD candidate SGT-003 receives Rare Pediatric Disease Designation | Image Credit: © Araki - © Araki - stock.adobe.com.

DMD candidate SGT-003 receives Rare Pediatric Disease Designation

April 2nd 2024
Article

The planned phase 1/2 INSPIRE Duchenne trial (NCT06138639) is a first in-human, open-label, multicenter trial to evaluate tolerability and safety of SGT-003.

© 2024 MJH Life Sciences

All rights reserved.